Vimarsana
Biggest News Aggregation in the World

Page 2 - Global Statistical Test News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Global Statistical Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Global Statistical Test Today - Breaking & Trending Today

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates - Vimarsana News

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates

Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the...

Applied Therapeutics Announces Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial, Company Plans to Meet with FDA Regarding Potential NDA Submission - Vimarsana News

Applied Therapeutics Announces Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial, Company Plans to Meet with FDA Regarding Potential NDA Submission

NEW YORK - Applied Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet... | April 25, 2023

Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission - Vimarsana News

Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission

Govorestat demonstrated consistent long-term clinical outcomes benefit across a range of functional measures in the ACTION-Galactosemia Kids trial, confirming prior biomarker dataGovorestat treatment... | June 18, 2023

Athira Pharma Presents Data from ACT-AD Phase 2 - Vimarsana News

Athira Pharma Presents Data from ACT-AD Phase 2

Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of...

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients at the Alzheimer's Association International Conference 2022 - Vimarsana News

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer's Patients at the Alzheimer's Association International Conference 2022

Additional data showed numerical improvement in activities of daily living , a protocoled secondary endpoint and a functional measure of independence Plasma biomarker data in a pre-specified... | August 3, 2022